Compound Planning Inc. Invests $483,000 in Moderna, Inc. $MRNA

Compound Planning Inc. bought a new stake in Moderna, Inc. (NASDAQ:MRNA) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,517 shares of the company’s stock, valued at approximately $483,000.

Several other institutional investors and hedge funds have also made changes to their positions in MRNA. Vanguard Group Inc. increased its stake in Moderna by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 41,584,782 shares of the company’s stock worth $1,226,335,000 after buying an additional 399,487 shares during the period. Capital World Investors purchased a new position in Moderna in the 4th quarter valued at about $378,299,000. Invesco Ltd. grew its stake in shares of Moderna by 15.7% during the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock valued at $212,223,000 after acquiring an additional 1,115,131 shares in the last quarter. Theleme Partners LLP grew its stake in shares of Moderna by 8.6% during the second quarter. Theleme Partners LLP now owns 7,868,810 shares of the company’s stock valued at $217,100,000 after acquiring an additional 626,420 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Moderna by 7.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,621,558 shares of the company’s stock worth $136,290,000 after acquiring an additional 309,126 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on MRNA. Morgan Stanley boosted their price target on Moderna from $33.00 to $39.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 8th. Piper Sandler lifted their price objective on Moderna from $69.00 to $77.00 and gave the stock an “overweight” rating in a report on Friday, June 26th. Barclays lifted their price objective on Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a report on Thursday, April 2nd. Royal Bank Of Canada increased their target price on Moderna from $38.00 to $45.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. Finally, Wolfe Research reissued an “underperform” rating and set a $25.00 price target on shares of Moderna in a research report on Monday, July 20th. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $40.00.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total transaction of $173,550.00. Following the completion of the sale, the insider owned 67,468 shares in the company, valued at $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Abbas Hussain sold 5,682 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $46.63, for a total transaction of $264,951.66. Following the sale, the director directly owned 12,066 shares in the company, valued at $562,637.58. This trade represents a 32.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 125,088 shares of company stock worth $6,193,713. Company insiders own 10.80% of the company’s stock.

Moderna Trading Down 2.4%

NASDAQ:MRNA opened at $54.49 on Thursday. The company has a quick ratio of 2.35, a current ratio of 2.41 and a debt-to-equity ratio of 0.08. The business’s 50 day moving average is $59.00 and its two-hundred day moving average is $52.33. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $85.60. The company has a market cap of $21.62 billion, a PE ratio of -6.69 and a beta of 0.94.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The firm had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. During the same quarter in the previous year, the business posted ($2.52) EPS. Moderna’s revenue was up 260.2% compared to the same quarter last year. On average, analysts predict that Moderna, Inc. will post -6.41 EPS for the current year.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.